Elicio Therapeutics, Inc.
Clinical-stage biotech developing lymph node-targeted immunotherapies for cancer.
ELTX | US
Overview
Corporate Details
- ISIN(s):
- US03476J1079 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 451 D STREET, 5TH FLOOR, 2210 BOSTON
- Website:
- https://elicio.com/
Description
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company that develops immunotherapies for cancer treatment. The company utilizes its proprietary Amphiphile (AMP) platform to deliver vaccines, immunomodulators, and adjuvants directly to the lymph nodes. This targeted-delivery approach is designed to bind therapeutic agents to albumin, a protein in the bloodstream, facilitating their transport to the immune system's central hubs. The goal is to generate a robust and durable immune response by activating and amplifying cancer-fighting T cells. Elicio's pipeline focuses on aggressive cancers, with a lead program in pancreatic ductal adenocarcinoma (PDAC).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Elicio Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Elicio Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Elicio Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
